Amylyx Pharmaceuticals, Inc. (AMLX) stock
AMLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$29.86−1.94 (-6.10%)
Close on Nov 12, 2026Market cap $3.33BP/E –Yield –
Amylyx Pharmaceuticals operating margin
Operating margin is operating income as a percentage of revenue.
Amylyx Pharmaceuticals's operating margin for the twelve months ending Sep 30, 2024 was -138.5%. For fiscal 2024 it was -360.2%, against 10.2% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -360.2% | −370.4 |
| FY2023 | Dec 31, 2023 | 10.2% | +915.9 |
| FY2022 | Dec 31, 2022 | -905.7% | +28107.6 |
| FY2021 | Dec 31, 2021 | -29013.3% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2024 | Sep 30, 2024 | -18187.7% | −18208.3 |
| Q1 FY2024 | Mar 31, 2024 | -137.8% | −134.9 |
| Q4 FY2023 | Dec 31, 2023 | 1.8% | +205.5 |
| Q3 FY2023 | Sep 30, 2023 | 18.2% | +15867.8 |
| Q2 FY2023 | Jun 30, 2023 | 20.6% | +8062.0 |
| Q1 FY2023 | Mar 31, 2023 | -2.9% | – |
| Q4 FY2022 | Dec 31, 2022 | -203.8% | – |
| Q3 FY2022 | Sep 30, 2022 | -15849.6% | – |
| Q3 FY2021 | Sep 30, 2021 | -8041.4% | – |
See a number that looks wrong?